Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15513076 | 1.00 | ALDH1A1 (0.47) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL6628924 | 1.00 | ALDH1A1 (0.47) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL15513075 | 1.00 | ALDH1A1 (0.47) | ALDH1A1PKMCA2CHKATDP1 | |
| Azepane SCHEMBL2266019 | 1.00 | ALDH1A1 (0.47) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL28317264 | 0.97 | ALDH1A1 (0.45) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL2721516 | 0.97 | ALDH1A1 (0.42) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL6826527 | 0.97 | ALDH1A1 (0.42) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL28873579 | 0.95 | ALDH1A1 (0.40) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL28258973 | 0.92 | ALDH1A1 (0.35) | ALDH1A1PKMCA2CHKATDP1 | |
| Trifluoroacetic Acid SCHEMBL15355467 | 0.92 | TSHR (0.37) | ALDH1A1PKMTDP1TSHRSLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350150-A | 4-Butoxyphenyl propenone and preparation method and application thereof | 北京茗泽中和药物研究有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-110382470-B | Preparation method of efavirenz | 纳尔逊·曼德拉都市大学 | 2023-06-06 | — | — | CN | claimed |
| CN-115974664-A | Synthesis method of 5-chloro-1-indanone | 合肥工业大学 | 2023-04-18 | — | — | CN | claimed |
| CN-110662746-B | Compounds as orally administered prodrugs of beta-lactamase inhibitors, pharmaceutical compositions thereof and use for treating bacterial infections | 阿里萨制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-3548469-B1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | UNIV NELSON MANDELA METROPOLITAN (ZA) | 2020-08-26 | — | — | EP | claimed |
| US-10689353-B2 | Method for the manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-06-23 | — | — | US | claimed |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2020-02-27 | — | — | US | claimed |
| CN-110382470-A | The preparation method of efavirenz | 纳尔逊·曼德拉都市大学 | 2019-10-25 | — | — | CN | claimed |
| EP-3548469-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | Nelson Mandela Metropolitan University (ZA) | 2019-10-09 | — | — | EP | claimed |
| WO-2018154414-A1 | METHOD FOR THE MANUFACTURE OF EFAVIRENZ | NELSON MANDELA METROPOLITAN UNIVERSITY (ZA) | 2018-08-30 | — | — | WO | claimed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | claimed |
| CN-100421665-C | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-10-01 | — | — | CN | claimed |
| CN-101228127-A | Novel Piperidine Derivatives | BANYU PHARMA CO LTD (JP) | 2008-07-23 | — | — | CN | claimed |
| CN-101056861-A | Carbamoyl-substituted spiro derivatives | BANYU PHARMA CO LTD (JP) | 2007-10-17 | — | — | CN | claimed |
| CN-1674906-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2005-09-28 | — | — | CN | claimed |
| CN-1552328-A | Use of phenoxthine compounds in preparing medicnies for inhibiting cancers and promoting radio-sensitive medicines | 中国人民解放军军事医学科学院放射医 | 2004-12-08 | — | — | CN | claimed |
| EP-0562815-A1 | Aromatic hydrocarbons separation from aromatic/non-aromatic mixtures | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1993-09-29 | — | — | EP | claimed |
| CN-107949384-B | Muscarinic agonists | 奈克斯拉制药英国有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-1090273-A | Acetogenin | GLAXO GROUP LTD (GB) | 1994-08-03 | — | — | CN | disclosed |
| CN-1073169-A | Acetogenin | GLAXO GROUP LTD (GB) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689353-B2 | Method for the manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | ALDH1A1 88/4885PKM 1078/4885CA2 4749/4885 |
| US-20200062722-A1 | Method For The Manufacture of Efavirenz | CYP2F1, CYP2D6, CYP3A4 | ALDH1A1 88/4885PKM 1078/4885CA2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.